MDxHealth to Present Third Quarter 2024 Financial Results and Corporate Update on November 6
MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, has announced it will release its financial results for the third quarter ended September 30, 2024, after market close on Wednesday, November 6, 2024. The company will host a conference call with live Q&A on the same day at 4:30pm ET / 22:30 CET.
The conference call will feature Michael K. McGarrity, Chief Executive Officer, and Ron Kalfus, Chief Financial Officer. Interested parties can access the call through various dial-in numbers provided for different countries or via a webcast link. A replay of the webcast will be available on the company's website following the conclusion of the live call.
MDxHealth SA (NASDAQ: MDXH), un'azienda di diagnostica di precisione in fase commerciale, ha annunciato che rilascerà i propri risultati finanziari per il terzo trimestre chiuso il 30 settembre 2024, dopo la chiusura del mercato di mercoledì 6 novembre 2024. L'azienda ospiterà una conferenza telefonica con sessione di domande e risposte in diretta lo stesso giorno alle 16:30 ET / 22:30 CET.
La conferenza telefonica vedrà la partecipazione di Michael K. McGarrity, Amministratore Delegato, e Ron Kalfus, Direttore Finanziario. Le parti interessate potranno accedere alla chiamata attraverso vari numeri di contatto forniti per diversi paesi o tramite un link per la trasmissione web. Una registrazione della trasmissione sarà disponibile sul sito web dell'azienda al termine della chiamata dal vivo.
MDxHealth SA (NASDAQ: MDXH), una empresa de diagnóstico de precisión en etapa comercial, ha anunciado que publicará sus resultados financieros para el tercer trimestre terminado el 30 de septiembre de 2024, después del cierre del mercado el miércoles 6 de noviembre de 2024. La empresa llevará a cabo una llamada de conferencia con preguntas y respuestas en vivo el mismo día a las 4:30 p. m. ET / 22:30 CET.
En la llamada de conferencia participarán Michael K. McGarrity, Director Ejecutivo, y Ron Kalfus, Director Financiero. Las partes interesadas pueden acceder a la llamada a través de varios números de acceso proporcionados para diferentes países o a través de un enlace de transmisión en vivo. Una grabación de la transmisión estará disponible en el sitio web de la empresa tras la conclusión de la llamada en vivo.
MDxHealth SA (NASDAQ: MDXH)는 상업 단계의 정밀 진단 회사로서, 2024년 9월 30일에 종료된 3분기 재무 결과를 2024년 11월 6일 수요일 시장 마감 후 발표할 것이라고 발표했습니다. 회사는 같은 날 오후 4시 30분 ET / 22시 30분 CET에 실시간 질의응답이 포함된 컨퍼런스 콜을 개최합니다.
컨퍼런스 콜은 Michael K. McGarrity, 최고경영자와 Ron Kalfus, 최고재무책임자가 진행합니다. 관심 있는 분들은 제공된 여러 국가별 전화 번호 또는 웹캐스트 링크를 통해 통화에 접속할 수 있습니다. 생방송 종료 후 회사 웹사이트에서 웹캐스트의 재생이 가능합니다.
MDxHealth SA (NASDAQ: MDXH), une entreprise de diagnostic de précision en phase commerciale, a annoncé qu'elle publiera ses résultats financiers pour le troisième trimestre clos le 30 septembre 2024, après la clôture du marché le mercredi 6 novembre 2024. L'entreprise organisera une conférence téléphonique avec questions et réponses en direct le même jour à 16h30 ET / 22h30 CET.
La conférence téléphonique mettra en vedette Michael K. McGarrity, Directeur Général, et Ron Kalfus, Directeur Financier. Les parties intéressées peuvent accéder à l'appel via divers numéros d'appel fournis pour différents pays ou via un lien de webinaire. Un enregistrement du webinaire sera disponible sur le site web de l'entreprise après la conclusion de l'appel en direct.
MDxHealth SA (NASDAQ: MDXH), ein Unternehmen für präzise Diagnostik in der kommerziellen Phase, hat bekannt gegeben, dass es seine finanziellen Ergebnisse für das dritte Quartal zum 30. September 2024 nach Börsenschluss am Mittwoch, den 6. November 2024 veröffentlichen wird. Das Unternehmen wird am selben Tag um 16:30 Uhr ET / 22:30 Uhr CET eine Konferenzschaltung mit Live-Q&A veranstalten.
In der Konferenzschaltung werden Michael K. McGarrity, Chief Executive Officer, und Ron Kalfus, Chief Financial Officer teilnehmen. Interessierte Parteien können über verschiedene Einwahlnummern aus verschiedenen Ländern oder über einen Webcast-Link auf die Sitzung zugreifen. Eine Wiederholung des Webcasts wird nach Abschluss des Live-Anrufs auf der Website des Unternehmens verfügbar sein.
- None.
- None.
MDxHealth to Present Third Quarter 2024 Financial Results
and Corporate Update on November 6
Company to Host Conference Call with Live Q&A, November 6, 2024, at 4:30pm ET / 22:30 CET
IRVINE, CA, and HERSTAL, BELGIUM – October 14, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the third quarter ended September 30, 2024, after market close on Wednesday, November 6, 2024.
| Title: | MDxHealth Presents Third Quarter 2024 Financial Results and Corporate Update Conference Call and Webcast |
| Speakers: | Michael K. McGarrity, Chief Executive Officer Ron Kalfus, Chief Financial Officer |
| Date: | November 6, 2024 |
| Time: | 4:30pm ET/ 22:30 CET |
| Conference Call Dial-in Details: | United States: 1-844-825-9789 Belgium: 0800 38 961 The Netherlands: 0800 94 94 506 United Kingdom: 0808 238 9064 |
| Conference ID: | 10193602 |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1692944&tp_key=8f9b7ff5cf |
The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company’s website.
About MDxHealth
Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company’s U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
| MDxHealth info@mdxhealth.com | |
| LifeSci Advisors (IR & PR) US: +1 949 271 9223 ir@mdxhealth.com |
NOTE: The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks or registered trademarks of MDxHealth SA. The GPS test was formerly known as and is frequently referenced in guidelines, coverage policies, reimbursement decisions, manuscripts and other literature as Oncotype DX Prostate, Oncotype DX GPS, Oncotype DX Genomic Prostate Score, and Oncotype Dx Prostate Cancer Assay, among others. The Oncotype DX trademark, and all other trademarks and service marks, are the property of their respective owners.
FAQ
When will MDxHealth (MDXH) release its Q3 2024 financial results?
What time is MDxHealth's (MDXH) Q3 2024 earnings call scheduled for?
Who will be speaking on MDxHealth's (MDXH) Q3 2024 earnings call?
How can I access MDxHealth's (MDXH) Q3 2024 earnings call?
